乌鸦传媒

WTX-124 demonstrated objective responses post-checkpoint blockade in phase I study

Monty Pal, MD, highlights various studies and current treatment approaches

Study tests second-line option for patients who progressed on immune checkpoint inhibitors

Researchers found link to certain pathways that affect immune modulation

Immune-mediated toxicities did not preclude an overall survival benefit, Jun Gong reports

INDIGO demonstrates major treatment advance for patients with IDH1/2-mutant disease

Study examined follow-up scans every 6-12 months instead of the standard 3-month interval